Why prosecuting Indian pharma patents could be even more difficult than it appears
A study released this month sheds new light on the Indian Patent Office’s (IPO’s) application of Section 3(d) of the country’s Patents Act – a controversial section intended to circumscribe the issue of ‘secondary’ rights for pharmaceuticals…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.